Factor X Nagoya 1 and Nagoya 2: a CRM– Factor X Deficiency and a Dysfunctional CRM+ Factor X Deficiency Characterized by Substitution of Arg306 by Cys and of Gly366 by Ser, respectively
Toshiyuki Miyata
1
National Cardiovascular Center Research Institute, Suita, Osaka
,
Tetsuhito Kojima
2
First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya
,
Kyoko Suzuki
3
School of Pharmaceutical Sciences, Kitasato University, Tokyo
,
Hideaki Umeyama
3
School of Pharmaceutical Sciences, Kitasato University, Tokyo
,
Tomio Yamazaki
2
First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya
,
Tadashi Kamiya
4
Japanese Red Cross Aichi Blood Center, Seto
,
Hideki Toyoda
5
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
,
Hisao Kato
1
National Cardiovascular Center Research Institute, Suita, Osaka
We have identified, in two unrelated patients, factor X deficiency that we have designated factor X Nagoya 1 and Nagoya 2, respectively. The proband with factor X Nagoya 1 showed factor X activity level of 3% and factor X antigen level <10% of the normal control value. All the exons and intron/exon junctions of the factor X gene were studied using a strategy combining polymerase chain reaction (PCR) amplification and nonradioactive single-strand conformational polymorphism (SSCP) analysis. Exon 8 containing DNA fragment of the proband with factor X Nagoya 1 showed aberrant migration on SSCP analysis. All exon-containing DNA fragments amplified by PCR were sequenced, and we identified a C-to-T substitution in exon 8 in the human factor X gene of the proband, which results in the replacement of Arg306 by Cys. This genetic defect has been transmitted from her father, and her sister also carried the same mutation; both showed almost half the normal levels of both factor X activity and antigen. The coordinates of human factor Xa indicated that Arg306 in the catalytic domain is positioned at the beginning of the alpha-helix near the second EFG-like domain. The substitution for Arg of Cys has been supposed to cause the destruction of local alpha-helix formation, possibly leading to the secretion problem. The proband with dysfunctional factor X Nagoya 2 was characterized by factor X activity level of 34% with normal factor X antigen level of 80%. We identified one substitution of G for A in exon 8 in the human factor X gene of the proband, which results in the replacement of Gly366 by Ser. As the Gly366 is positioned at the primary substrate binding pocket, the replacement of Gly with Ser would cause a defect of substrate binding, leading to the loss of enzymatic activity.
References
1
Watzke HH,
High KA.
Factor X.. In: Molecular basis of thrombosis and hemostasis..
High KA,
Robert HR.
(eds).
Marcel Dekker; New York: 1995. pp 239-55.
2
McMullen BA,
Fujikawa K,
Kisiel W,
Sasagawa T,
Howald WN,
Kwa EY,
Weinstein B.
Complete amino acid sequence of the light chain of human blood coagulation factor X: Evidence for identification of residue 63 as β-hydroxyaspartic acid.. Biochemistry 1983; 22: 2875-84.
4
Fung MR,
Hay CW,
MacGillivray RTA.
Characterization of an almost full-length cDNA coding for human blood coagulation factor X.. Proc Natl Acad Sci USA 1985; 82: 3591-5.
5
Messier TL,
Pittman DD,
Long GL,
Kaufman RJ,
Church WR.
Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X.. Gene 1991; 99: 291-4.
6
Leytus SP,
Foster DC,
Kurachi K,
Davie EW.
Gene for human factor X: A blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C.. Biochemistry 1986; 25: 5098-102.
7
Jagadeaswaran P,
Reddy SV,
Rao KJ,
Hamsabhushanam K,
Lyman G.
Cloning and characterization of the 5’ end (exon 1) of the gene encoding human factor X.. Gene 1989; 84: 517-9.
10
Watzke HH,
Wallmark A,
Hamaguchi N,
Giardina P,
Stafford DW,
High KA.
Factor XSanto Domingo: Evidence that the severe clinical phenotype arises from a mutation blocking secretion.. J Clin Invest 1991; 88: 1685-9.
11
Racchi M,
Watzke HH,
High KA,
Lively MO.
Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum.. J Biol Chem 1993; 268: 5735-40.
12
Watzke HH,
Lechner K,
Roberts HR,
Reddy SV,
Welsch DJ,
Friedman P,
Mahr G,
Jagadeeswaran P,
Monroe DM,
High KA.
Molecular defect (Gla+14→Lys) and its functional consequences in a hereditary factor X deficiency (factor X “Vorarlberg”).. J Biol Chem 1990; 265: 11982-9.
13
Kim DJ,
Thompson AR,
James HL.
Factor X Ketchikan: a variant molecule in which Gly replaces a Gla residue at position 14 in the light chain.. Hum Genet 1995; 95: 212-4.
14
Wallmark A,
Larson P,
Ljung R,
Monroe D,
High KA.
Molecular defect (Gla 26-Asp) and its functional consequences in a hereditary FX deficiency (factor X “Malmö 4”).. Blood 1991; 78 (Suppl. 01) 229a.
16
Wallmark A,
Ho C,
Monroe DM,
Tengborn L,
High KA.
Molecular defect in FX. “Ockero”, a mild congenital FX deficiency.. Thromb Haemost 1991; 65: 1263.
17
Morishita E,
Takemoto K,
Asakura E,
Saito M,
Sadakaji Y,
Uotani C,
Kumabashiri I,
Yamasaki M,
Aoshima K,
Matsuda T,
Hashimoto T,
Yamaguchi K.
Genetic analysis of congenital factor X deficiency (factor X Kanazawa).. Int J Hematol 1995; 61: 293.
18
Watzke HH,
Lechner K,
Larson P,
High KA.
Factor XVienna molecular analysis and in vitro expression of a severe CRM (-) FX deficiency.. Thromb Haemost 1993; 69: 752.
19
Messier TL,
Wong C,
Bovill EG,
Long GL,
Church WR.
Factor X Stockton: A missense mutation (GAC to AAC) of the serine protease active site aspartic acid to asparagine.. Thromb Haemost 1993; 69: 751.
20
Reddy SV,
Zhou ZQ,
Rao KJ,
Scott JP,
Watzke H,
High KA,
Jagadeeswaran P.
Molecular characterization of human factor XSan Antonio.. Blood 1989; 74: 1486-90.
21
Bezeaud A,
Miyata T,
Helley D,
Zeng YZ,
Kato H,
Aillaud MF,
Juhan-Vague I,
Guillin MC.
Functional consequences of the Ser334 Pro mutation in a human factor X variant (factor XMarseille).. Eur J Biochem 1995; 234: 140-7.
22
Marchetti G,
Castaman G,
Pinotti M,
Lunghi B,
di Iasio MG,
Ruggieri M,
Rodeghiero F,
Bernardi F.
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glu102Lys) in the second EGF-like domain.. Br J Haematol 1995; 90: 910-5.
23
James HL,
Girolami A,
Fair DS.
Molecular defect in coagulation factor XFriuli results from a substitution of serine for proline at position 343.. Blood 1991; 77: 317-23.
24
Dati F,
Barthels M,
Conard J,
Fluckiger J,
Girolami A,
Hanseler E,
Huber J,
Keller F,
Kolde HJ,
Muller-Berghaus G,
Samama M,
Thiel W.
Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time.. Thromb Haemost 1987; 58: 856-65.
26
Miyata T,
Zhen YZ,
Sakata T,
Tsushima N,
Kato H.
Three missense mutations in the protein C heavy chain causing type I and type II protein C deficiency.. Thromb Haemost 1994; 71: 32-7.
27
Orita M,
Suzuki Y,
Sekiya T,
Hayashi K.
Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.. Genomics 1989; 5: 874-9.
28
Miyata T,
Sakata T,
Zhen YZ,
Tsukamoto H,
Umeyama H,
Uchiyama S,
Ikusaka M,
Yoshioka A,
Imanaka Y,
Fujimura H,
Kambayashi J,
Kato H.
Genetic characterization of protein C deficiency in Japanese subjects using a rapid and nonradioactive method for single-stand conformational polymorphism analysis and a model building.. Thromb Haemost 1996; 76: 302-11.
29
Padmanabhan K,
Padmanabhan KP,
Tulinsky A,
Park CH,
Bode W,
Huber R,
Blankenship DT,
Cardin AD,
Kisiel W.
Structure of human des(1-45) factor Xa at 2.2 Å resolution.. J Mol Biol 1993; 232: 947-66.
